Nature Communications (Nov 2019)
Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant
- Qipan Deng,
- Hui Hu,
- Xinfang Yu,
- Shuanglin Liu,
- Lei Wang,
- Weiqun Chen,
- Chi Zhang,
- Zhaoyang Zeng,
- Ya Cao,
- Zijun Y. Xu-Monette,
- Ling Li,
- Mingzhi Zhang,
- Steven Rosenfeld,
- Shideng Bao,
- Eric Hsi,
- Ken H. Young,
- Zhongxin Lu,
- Yong Li
Affiliations
- Qipan Deng
- Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine
- Hui Hu
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic
- Xinfang Yu
- Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine
- Shuanglin Liu
- Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine
- Lei Wang
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic
- Weiqun Chen
- Department of Medical Laboratory, Central Hospital of Wuhan
- Chi Zhang
- Department of Medical Laboratory, Central Hospital of Wuhan
- Zhaoyang Zeng
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic
- Ya Cao
- Key Laboratory of Carcinogenesis and Invasion, Ministry of Education, Xiangya Hospital; Cancer Research Institute, Xiangya School of Medicine, Central South University; Key Laboratory of Carcinogenesis, Chinese Ministry of Health
- Zijun Y. Xu-Monette
- Department of Pathology, Division of Hematopathology, Duke University Medical Center
- Ling Li
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University; Lymphoma Diagnosis and Treatment Center of Henan Province
- Mingzhi Zhang
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University; Lymphoma Diagnosis and Treatment Center of Henan Province
- Steven Rosenfeld
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic
- Shideng Bao
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic
- Eric Hsi
- Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic
- Ken H. Young
- Department of Pathology, Division of Hematopathology, Duke University Medical Center
- Zhongxin Lu
- Department of Medical Laboratory, Central Hospital of Wuhan
- Yong Li
- Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine
- DOI
- https://doi.org/10.1038/s41467-019-13002-x
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
TP53 mutations can cause increased risk for cancers. Here, the authors show a noncoding polymorphism in TP53 increases risk of some cancers but delays onset of others, and in a mouse model show this is via alteration of microRNA targeting sites that differ in impact depending on the tissue.
